Ahn M-J et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01. ESMO Asia 2023;Abstract 509MO.

Ahn M-J et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389(22):2063-75. Abstract

Benjamin DJ et al. The role of chemotherapy plus immune checkpoint inhibitors in oncogenic-driven NSCLC: A University of California Lung Cancer Consortium retrospective study. JTO Clin Res Rep 2022;3(12):100427. Abstract

Besse B et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: A phase 2 umbrella trial. Nat Med 2024;30(3):716-29. Abstract

Cascone T et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med 2024;390(19):1756-69. Abstract

de Castro G Jr et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with NSCLC and PD-L1 tumor proportion score ≥1% in the KEYNOTE-042 study. J Clin Oncol 2023;41(11):1986-91. Abstract

Dowlati A et al. Sacituzumab govitecan as second-line treatment for extensive SCLC: Preliminary results from the phase II TROPiCS-03 basket trial. ESMO 2023;Abstract 1990MO.

Filippi AR et al. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: Interim analysis of overall survival from PACIFIC-R. ESMO Open 2024;9(6):103464. Abstract

Filippi ARR et al. Durvalumab after radiotherapy in patients with unresectable stage III NSCLC ineligible for chemotherapy: Primary results from the DUART study. ESMO 2023;Abstract LBA62.

Garassino MC et al. Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). ASCO 2024;Abstract 8012.

Garassino MC et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous NSCLC: 5-year outcomes from the phase III KEYNOTE-189 study. J Clin Oncol 2023;41(11):1992-8. Abstract

Goto Y et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). ASCO 2023;Abstract 9004.

Heymach J et al. Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN. ASCO 2024;Abstract 8011.

Johnson ML et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for mNSCLC: The phase III POSEIDON study. J Clin Oncol 2023;41(6):1213-27. Abstract

Khan S et al. ctDNA-Lung-DETECT: ctDNA outcomes for resected early-stage non-small cell lung cancers at 12 months. ASCO 2024;Abstract 8018.

Lee S-H et al. A phase II, open-label, combination therapy of durvalumab and ceralasertib in relapsed and refractory small cell lung cancer (SUKSES-N4). ASCO 2024;Abstract 8104.

Levy BP et al. Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02. ASCO 2024;Abstract 8617.

Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.

Lu S et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 2024;[Online ahead of print]. Abstract

Novello S et al. Pembrolizumab plus chemotherapy in squamous NSCLC: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol 2023;41(11):1999-2006. Abstract

Paz-Ares L et al. Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): Outcomes by PD-L1 expression and tissue tumor mutational burden. Clin Cancer Res 2024;30(4):824-35. Abstract

Paz-Ares L et al. Tarlatamab for patients with previously treated SCLC: Primary analysis of the phase II DeLLphi-301 study. ESMO 2023;Abstract LBA92.

Paz-Ares L et al. TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). ESMO 2023;Abstract 1314MO.

Peters S et al. Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line metastatic (m) NSCLC: 5-year overall survival (OS) update from the POSEIDON study. ESMO Immuno-Oncology Congress 2023;Abstract LBA3.

Planchard D et al. ICARUS-LUNG01: A phase 2 study of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. ASCO 2024;Abstract 8501.

Provencio M et al. Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study. ASCO 2024;Abstract LBA8007.

Ramalingam SS et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. ASCO 2024;Abstract LBA4.

Reck M et al. Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA. ASCO 2024;Abstract 8560.

Rodrigues G et al. American Radium Society appropriate use criteria for unresectable locally advanced non-small cell lung cancer. JAMA Oncol 2024;[Online ahead of print]. Abstract

Spicer J et al. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. ASCO 2024;Abstract LBA8010.

Spigel DR et al. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). ASCO 2024;Abstract LBA5.

Wakelee H et al. Perioperative pembrolizumab for early-stage NSCLC. N Engl J Med 2023;389(6):491-503. Abstract